Alaunos Therapeutics Business Summary

Alaunos Therapeutics, Inc. (TCRT) is a micro-cap biopharmaceutical company that has undergone a definitive strategic pivot from its legacy TCR-T cell therapy oncology platform to a preclinical-stage focus on obesity and metabolic health. The company’s primary business model centers on the development of its lead candidate, ALN1003, a differentiated, non-hormonal, and non-incretin oral small-molecule therapy designed to treat obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Alaunos currently generates negligible revenue, with trailing twelve-month figures under $10,000, and operates as a development-stage entity reliant on capital markets, strategic licensing agreements, or potential acquisition for survival. Its competitive landscape includes established cell therapy firms like Adaptimmune Therapeutics and Iovance Biotherapeutics, as well as metabolic-focused peers such as Dyadic International and BriaCell Therapeutics; Alaunos distinguishes itself by pursuing an oral, non-hormonal mechanism of action in a market dominated by injectable GLP-1 receptor agonists. Leadership is currently headed by Holger Weis, who was appointed Chief Executive Officer in July 2025 after serving as a long-term board member and life sciences consultant. The board of directors includes Lead Independent Director Heidi Hagen, Michael A. Jerman (Audit Chair), Jaime Vieser, and Robert W. Postma. The company’s pedigree traces back to its 1998 founding as Ziopharm Oncology by Dr. Jonathan Lewis, a legacy that provided the foundational "Sleeping Beauty" transposon system before the 2023-2025 restructuring. Notable institutional backing includes positions held by MSD Partners L.P., The Vanguard Group, and BlackRock. As of March 2026, the company is navigating a significant governance challenge following a $7 million change-of-control investment proposal from an activist shareholder group led by Adrian Price (HexagonONE Ltd), which seeks to appoint Gerald Bruce to the board and reshape the company’s strategic trajectory.